一线伊布替尼联合维奈克拉治疗非母细胞型套细胞淋巴瘤:≥65岁或TP53突变患者
SYMPATICO研究开放标签队列评估一线伊布替尼联合维奈克拉治疗非母细胞型套细胞淋巴瘤,纳入≥65岁(n=65)或TP53突变(n=11)患者共78例。中位随访40.5个月,完全缓解率69%,总缓解率95%,中位无进展生存40.2个月,3年总生存79%。
要点
- 一线伊布替尼联合维奈克拉在非母细胞型套细胞淋巴瘤中显示高完全缓解率和持久缓解。
- ≥65岁无TP53突变患者完全缓解率76%,中位无进展生存40.2个月。
- ≥65岁伴TP53突变患者完全缓解率44%,中位无进展生存22.0个月。
核心结论
- 一线伊布替尼联合维奈克拉在初治非母细胞型套细胞淋巴瘤中显示有前景的疗效,完全缓解率高且缓解持久,可能成为≥65岁或任何年龄TP53突变患者的选择。
研究设计与样本
- 3期SYMPATICO研究开放标签队列,纳入非母细胞型套细胞淋巴瘤患者,≥65岁65例或≥18岁伴TP53突变11例,共78例。
- 治疗方案为口服伊布替尼560 mg每日一次联合维奈克拉(5周递增至400 mg每日一次)治疗2年,随后伊布替尼560 mg单药治疗直至疾病进展或不可接受毒性。
主要发现
- 中位研究时间40.5个月,完全缓解率69%(95%CI 58-79),总缓解率95%(95%CI 87-99)。
- 中位缓解持续时间37.1个月(95%CI 30.3至不可估计),中位无进展生存40.2个月(95%CI 29.4至不可估计),中位总生存未达到,3年总生存率79%(95%CI 68-86)。
- ≥65岁无TP53突变患者完全缓解率76%,中位无进展生存40.2个月,3年总生存85%;伴TP53突变患者完全缓解率44%,中位无进展生存22.0个月,3年总生存66%。
- <65岁伴TP53突变患者完全缓解率73%,中位无进展生存15.4个月,3年总生存73%。
- 最常见治疗中出现的不良事件为腹泻(49%)、疲乏(37%)、中性粒细胞减少(35%)和COVID-19(32%)。
关键数值与推荐
- 完全缓解率69%(95%CI 58-79),总缓解率95%(95%CI 87-99)。
- 中位无进展生存40.2个月(95%CI 29.4至不可估计),3年总生存率79%(95%CI 68-86)。
临床怎么用
- 对于≥65岁或任何年龄伴TP53突变的初治非母细胞型套细胞淋巴瘤患者,可考虑一线伊布替尼联合维奈克拉方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phase 3 SYMPATICO study included an open-label cohort to evaluate first-line ibrutinib plus venetoclax in patients with nonblastoid mantle cell lymphoma (MCL) aged ≥65 years (n = 65) or ≥18 years with a TP53 mutation (TP53m; n = 11). Eligible patients received oral ibrutinib 560 mg once daily and venetoclax (5-week ramp-up to 400 mg once daily) for 2 years, then single-agent ibrutinib 560 mg until disease progression or unacceptable toxicity. In total, 78 patients were enrolled. With a median time on study of 40.5 months, the complete response (CR) rate was 69% (95% confidence interval [CI], 58-79), and the overall response rate was 95% (95% CI, 87-99). The median duration of response was 37.1 months (95% CI, 30.3 to not estimable [NE]). The median progression-free survival (mPFS) was 40.2 months (95% CI, 29.4 to NE); median overall survival (OS) was not reached (3-year OS rate, 79% [95% CI, 68-86]). In patients aged ≥65 years, CR rates were 76% (no TP53m) and 44% (with TP53m), mPFS was 40.2 and 22.0 months, and 3-year OS was 85% and 66%, respectively. In adult patients aged <65 years (with TP53m), the CR rate was 73%, mPFS was 15.4 months, and 3-year OS was 73%. The most common treatment-emergent adverse events were diarrhea (49%), fatigue (37%), neutropenia (35%), and COVID-19 (32%). First-line ibrutinib plus venetoclax showed promising efficacy, with high CR rates and durable remissions, in patients with previously untreated nonblastoid MCL and may be an option for patients aged ≥65 years or patients of any age with TP53m. The trial was registered at www.clinicaltrials.gov as NCT03112174.
引用
- Wang M, Hoffmann M, Wrobel T, et al. First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations. Blood. 2026. PMID: 42462092. doi:10.1182/blood.2025032833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。